CHARM Therapeutics Company
Charm Therapeutics designs and develops a new generation of small-molecule therapeutics that target the interaction between menin and the KMT2A protein, a key driver of acute myeloid leukemia (AML), using its proprietary AI-powered platform called DragonFold. The company’s lead program is a menin inhibitor optimized to maintain activity against all known clinical resistance mutations while minimizing safety and drug-interaction risks. Charm Therapeutics employs protein-ligand co-folding intelligence to inform molecular design, advancing its pipeline from preclinical stages toward the clinic.
Investors
Connections from
Total Funding:
162690588
Founded Date:
2021-01-01
Industry:
Quantum Biology
Employee Number:
11-50
Last Funding Date:
2025-09-02
Funding Status:
private
Headquarters:
London,England,United Kingdom,Europe
Super Industry:
Quantum Science Applications
Funding Stage:
Early Stage Venture
Funding Total Value:
162690588
Last Funding Total Usd:
80000000
Last Funding Total Currency:
USD
Last Funding Total Value:
80000000
Founders:
David Baker,Laksh Aithani